Vaxcyte, Inc.
PCVX· Nasdaq
Released Feb 27, 2024, after the close
10-K filed Feb 27, 2024, 58 days after period end · 0000950170-24-021145
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Net Income | -$180.80M | -$78.05M | -$28.56M | -$20.74M |
| EPS Diluted | — | — |
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR
| — |
| -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.